Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 33% less
These brands contain the same active ingredient (Ciprofibrate). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Tgdrop is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Adults: The recommended dose is Ciprofbrate 100 mg per day. This dose should not be exceeded.Patients with renal insufficiency: In moderate renal impairment (creatinine clearance 30-80 ml/min/1.73 m2) it is recommended that dosage be reduced to one tablet every other day. Patients should be carefully monitored. Ciprofbrate should not be used in severe renal impairment (creatinine clearance <30 ml/min/1.73 m2). Patients with hepatic insufficiency: Use with caution in patients with impaired hepatic function. Ciprofbrate treatment should be discontinued in case of increased AST and ALT levels to more than 3 times the upper limit of normal or if cholestatic liver injury is evidenced.Elderly: As for adults but precautions should be taken for Age more than 70 years.Paediatric population: Not recommended since safety and efficacy in children has not been established.
Side Effects
Headache, Dizziness, Somnolence, Vertigo, Nausea, Vomiting, Diarrhoea, Dyspepsia, Abdominal pain, Rash, Alopecia, Myalgia, Fatigue.
Cautions & Contraindications
Warnings & Precautions
Special warnings: Patients with rare hereditary problems of galactose intolerance, lactose deficiency or glucose-galactose malabsorption should not take this medicine.Myalgia/myopathy: Patients should be advised to report unexplained muscle pain, tenderness or weakness immediately.Patients with impaired hepatic function: Periodic hepatic function tests are recommended (every 3 months for the first 12 months of treatment). Ciprofbrate treatment should be discontinued in case of increased AST and ALT levels to more than 3 times the upper limit of normal or if cholestatic liver injury is evidenced.
Contraindications
Hypersensitivity to the active substance or to any of the excipients Severe hepatic impairment Severe renal impairment (creatinine clearance <30 ml/min/1.73 m2) Pregnancy and lactation or when pregnancy is suspected Concurrent use with another fibrate